Novavax is a biotechnology company that has been making headlines recently for its COVID-19 vaccine candidate, called NVX-CoV2373. The vaccine has shown promising results in clinical trials and has received authorization for emergency use in multiple countries.
However, Novavax is not just focused on COVID-19. The company has a robust pipeline of vaccine candidates for other diseases, including respiratory syncytial virus (RSV) and influenza.
To help ensure that these vaccines can be manufactured and distributed efficiently, Novavax has entered into a supply agreement with a contract development and manufacturing organization (CDMO) called AGC Biologics.
Under the terms of the agreement, AGC Biologics will manufacture the antigen component of Novavax`s vaccine candidates. The antigen is the part of the vaccine that stimulates the immune system to produce antibodies against the disease.
AGC Biologics has extensive experience in manufacturing biologics, including vaccines, and has facilities in multiple countries. This partnership will help to ensure that Novavax`s vaccine candidates can be produced at scale and made available to patients worldwide.
Novavax`s CEO, Stanley C. Erck, commented on the agreement, saying, “Our partnership with AGC Biologics is an important step in expanding the global supply chain for NVX-CoV2373 and our other vaccine candidates. AGC Biologics` expertise and track record in manufacturing biologics will be critical in ensuring the availability of these life-saving vaccines.”
This supply agreement is just one example of the complex logistics involved in vaccine development and distribution. As the world continues to grapple with the COVID-19 pandemic, it is important to remember that there are many other infectious diseases that threaten public health. Novavax`s work on RSV and influenza vaccines, and partnerships like the one with AGC Biologics, will be crucial in fighting these diseases and protecting public health in the years to come.